International Conference Of
Portugal, 8th, 9th May, 2015
Alternatives to Animal Experimentation
Dr. Philip Low is the inventor, neurotechnologist and computational neuroscientist responsible for the SPEARS algorithm, the iBrain neural monitor and the Cambridge Declaration on Consciousness. At the University of Chicago, he invented novel neurosurgical techniques. At Harvard Medical School, he showed in 9 weeks that a collagen inhibitor could successfully neutralize the growth of fibroid tumors - he was 19 years old at the time. At the Salk Institute, which he joined at the recommendation of the late Francis Crick, Nobel Laureate of DNA fame, and where he was a Sloan-Swartz, Swartz and Kavli fellow, he invented the SPEARS algorithm and authored a doctoral dissertation which overturned long-standing beliefs regarding the nature of human and animal neural sleep patterns and made possible the automated and non-invasive single channel detection of REM sleep, cortical and subcortical patterns, providing the foundation for iBrain and the Cambridge Declaration on Consciousness, which recognized the overwhelming neurobiological similarities between human and non-human animals. The body of his PhD thesis, a dynamic map of brain activity derived from a single non-invasive EEG channel, was a single page long and was unanimously approved by a committee including four members of the National Academy of Sciences and two past Presidents of the Society for Neuroscience. His work has been featured in technical and popular articles including The Proceedings of the National Academy of Sciences, CNN, The Economist, The New York Times and TIME.
While still in his twenties, Dr. Low was appointed to dual appointments at the Stanford School of Medicine and the MIT Media Lab and was named President of the 1st International Congress on Alzheimer's Disease and Advanced Neurotechnologies, held in Monaco in February 2010. Dr. Low also chaired the first Francis Crick Memorial Conference in Cambridge, UK, in 2012 and is an advisor to the White House and the USISTF on matters of Neuroscience, Health and Technology. To bring his innovations to the market, Dr. Low founded NeuroVigil, the neurodiagnostics company responsible for iBrain, a wireless portable neural monitoring and analytics platform, used by the Pharmaceutical Industry, Government and Academia to monitor non-invasively and remotely neuropathologies such as Alzheimer's, Autism, Depression, Epilepsy, Gulf War Syndrome, OCD, Parkinson's, PTSD, TBI and Rett Syndrome, as well as the response of drugs affecting the brain, and to restore loss of function, such as communication, including in ALS patients. Dr. Low founded NeuroVigil when he was still in graduate school and enlisted several Nobel Laureates and Fortune 100 company founders. Under Dr. Low's leadership, NeuroVigil won the 2008 DFJ Venture and UCSD Entrepreneur Challenges, successfully launched the first outpatient clinical trial for a CNS drug in 2009, won the CONNECT Most Innovative New Product in the Life Sciences Award in 2010, closed a financing round at an unprecedented seed valuation on May 1st 2011, began a partnership with Stephen Hawking on Brain Based Communication systems, was recognized by The Washington Post and Fast Company as one the Top 10 Most Innovative Companies in Health Care, alongside GE and the Cleveland Clinic, and in 2012, its "sleep mining technology" was listed by The New York Times as one of "32 Innovations that Will Change Your Tomorrow". He holds numerous patents and three "extraordinary ability" clearances from the US government, is a 2010 MIT Technology Review TR-35 Top Young Innovator, an honor shared with the Founders of Google, Linux and Facebook, became in 2011, the Inaugural Jacobs-Rady Pioneer for Global Innovation and Entrepreneurship, awarded every five years to an outstanding tech innovator and Chairman/CEO, and was singled out in 2013 by The Scientist Magazine as "A Scientist to Watch". In the Fall of 2013, NeuroVigil expanded its operations to NASA.
Bas Blaauboer (1949) studied biology at Utrecht University and did a PhD in toxicology at the same university (1978). He spent a postdoctoral year at the MRC Toxicology Unit in the UK (1979), and when he returned to Utrecht led a group on in vitro toxicology (biochemical and cellular toxicology), first in the Department of Veterinary Pharmacology and Toxicology. Later the research in toxicology was moved to the interfacultary Research Institute for Toxicology (RITOX), which after a merger in 2000 became a part of the Institute of Risk Assessment Sciences (IRAS).
In 2008 he was appointed to the Doerenkamp-Zbinden Chair on “Alternatives to Animal Testing in Toxicological Risk Assessment”, which is located in IRAS. His research focused on the use of in vitro toxicity data in combination with physiologically based biokinetic (PBBK) modelling as tools in risk assessments.
He is author or co-author of over 180 publications (peer-reviewed papers or book chapters), reports and editorials.
He was the recipient of the Willy van Heumen award 2013 for his continuing work on promoting alternatives to laboratory animal use in toxicology.
He was director/coordinator for the Dutch Programme for Postgraduate Education in Toxicology from 2013 until his retirement from Utrecht University on January 1, 2014. He continues to hold the Editorship for Toxicology in Vitro.